Literature DB >> 32179156

Are preoperative depression and anxiety associated with patient-reported outcomes, health care payments, and opioid use after anterior discectomy and fusion?

Andrew B Harris1, Majd Marrache1, Varun Puvanesarajah1, Micheal Raad1, Amit Jain1, Khaled M Kebaish1, Lee H Riley1, Richard L Skolasky2.   

Abstract

BACKGROUND CONTEXT: Depression and anxiety are common psychiatric conditions among US adults, and anterior cervical discectomy and fusion (ACDF) is one of the most commonly performed spinal surgeries. Mental health conditions can affect physical health, and thus have the potential to contribute to adverse outcomes after spine surgery; however, a comprehensive assessment of long-term outcomes and the additive economic burden of these conditions in patients undergoing ACDF has not been well described.
PURPOSE: Our goal was to assess the associations between depression/anxiety and adverse outcomes and health-resource utilization after anterior cervical discectomy and fusion (ACDF). STUDY
DESIGN: Retrospective database study. PATIENT SAMPLE: We retrospectively analyzed a private administrative health claims database to identify patients who underwent ACDF in the United States from 2010 to 2013. A total of 16,306 patients met our inclusion criteria. Mean (± standard deviation) patient age was 50±7.9 years. Approximately 4,800 patients (30%) had a depression diagnosis and 4,000 (25%) had a diagnosis of anxiety. OUTCOME MEASURES: The primary outcomes of interest were intensive care unit admission, multiday hospitalization, discharge disposition, 30- and 90-day hospital readmission, 1- and 2-year rates of revision surgery, and chronic postoperative opioid use. Secondary outcomes were 1- and 2-year total cumulative health care payments and cumulative postoperative opioid consumption.
METHODS: Regression models controlled for demographic and medical covariates, alpha=0.05.
RESULTS: A preoperative diagnosis of depression was associated with higher odds of multiday hospitalization (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.01-1.19), 90-day readmission (OR 1.71, 95% CI 1.46-2.02), revision surgery within 2 years (OR 1.43 95% CI 1.16-1.76), and chronic postoperative opioid use (OR 1.58, 95% CI 1.45-1.72) and an increase of $5,915 in adjusted 2-year health care payments (p<.001). Patients with a preoperative diagnosis of anxiety had higher odds of multiday hospitalization (OR 1.15, 95% CI 1.06-1.25), revision surgery within 2 years (OR 1.33, 95% CI 1.07-1.65), and chronic postoperative opioid use (OR 1.62, 95% CI 1.48-1.77) and an increase of $4,471 in adjusted 2-year health care payments (p<.001). Neither anxiety nor depression was associated with intensive care unit admission, discharge disposition, 30-day readmission, revision surgery within 1 year, 1-year cumulative health care payments, or cumulative postoperative opioid consumption.
CONCLUSIONS: Patients with preoperative diagnoses of depression or anxiety have a greater likelihood of adverse outcomes, increased opioid consumption, and increased cumulative health care payments after ACDF compared with patients without depression or anxiety.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anterior cervical discectomy and fusion; Anxiety; Depression; Health care payments; Outcomes

Mesh:

Substances:

Year:  2020        PMID: 32179156     DOI: 10.1016/j.spinee.2020.03.004

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  7 in total

1.  Workers compensation patients experiencing depression report meaningful improvement in mental health scores after anterior cervical discectomy and fusion.

Authors:  Timothy J Hartman; James W Nie; Keith R MacGregor; Omolabake O Oyetayo; Eileen Zheng; Kern Singh
Journal:  J Clin Orthop Trauma       Date:  2022-09-11

2.  Impact of Depression Severity on Patient-Reported Outcome Measures Following Multilevel Anterior Cervical Discectomy and Fusion.

Authors:  Elliot D K Cha; Conor P Lynch; Caroline N Jadczak; Shruthi Mohan; Cara E Geoghegan; Kern Singh
Journal:  Int J Spine Surg       Date:  2022-02-17

3.  The impact of preoperative motor weakness on postoperative opioid use after ACDF.

Authors:  Hannah A Levy; Brian A Karamian; Jeffrey Henstenburg; Joseph Larwa; Jose A Canseco; Brett Haislup; Michael Chang; Parthik Patel; Kris E Radcliff; Barrett I Woods; Mark F Kurd; Alan S Hilibrand; Christopher K Kepler; Alexander R Vaccaro; Gregory D Schroeder
Journal:  J Orthop       Date:  2021-06-30

4.  Manifestation of Borderline Personality Symptomatology in Chronic Pain Patients Under Stress: An Understated and Exacerbated Consequence of the COVID-19 Crisis.

Authors:  Hannah Shapiro; Ronald J Kulich; Michael E Schatman
Journal:  J Pain Res       Date:  2020-06-15       Impact factor: 3.133

5.  Opioid-free anesthesia for patients with joint hypermobility syndrome undergoing craneo-cervical fixation: a case-series study focused on anti-hyperalgesic approach.

Authors:  Carlos Ramírez-Paesano; Albert Juanola Galceran; Claudia Rodiera Clarens; Vicenҫ Gilete García; Bartolomé Oliver Abadal; Verónica Vilchez Cobo; Bibiana Ros Nebot; Sara Julián González; Lucía Cao López; Jesús Santaliestra Fierro; Josep Rodiera Olivé
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

6.  A national snapshot of the impact of clinical depression on post-surgical pain and adverse outcomes after anterior cervical discectomy and fusion for cervical myelopathy and radiculopathy: 10-year results from the US Nationwide Inpatient Sample.

Authors:  Jiang Chen; Jin-Yu Li; Gui-Hua Tian; Rui-Jin Qiu; Xue-Qian Zhao; Xue-Shi Di; Qiao-Mei Yuan; Shui-Wen Long; Yu Ran; Yu-Song Jia; Hong-Cai Shang
Journal:  PLoS One       Date:  2021-10-15       Impact factor: 3.240

7.  Is depression the contraindication of anterior cervical decompression and fusion for cervical spondylosis?

Authors:  Xiaolu Chen; Xiao Li; Yu Gan; Ying Lu; Yu Tian; Yixiao Fu; Hanjie Yang; Ke Liu; Yinlian Pan; Xing Du
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.